NOT-TR-20-029: Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Heath Need

Applications accepted on rolling basis through November 10, 2020

Funder: NIH: National Center for Advancing Translational Sciences (NCATS)

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the need for projects that address the coronavirus disease 2019 (COVID-19) Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients as follows:

FOA

Responsive Activity

Expected Number of Awards

RFA-TR-17-006 CTSA Program Data to Health (CD2H) Coordinating Center (U24)

Digital health platforms and models that integrate data, assess risk, and provide illness/infection surveillance, management tools, and inform clinical practice

1

RFA-TR-15-002 CTSA Network - Trial Innovation Centers (TICs) (U24)

RFA-TR-15-004 Clinical and Translational Science Award (CTSA) Network Recruitment Innovation Centers (RICs) (U24)

Planning of COVID-19 trials; additional recruitment and retention support; eConsent support; and provision of a platform and statistical expertise to collect and perform meta-analyses of COVID-19 therapeutic trials; collection and analysis of COVID-19 health records

1-2

UL1 Components Only

PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)

PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)

PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)

RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)

Support of the NCATS National COVID Cohort Collaborative (N3C): Provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data (awards anticipated to be $50,000 to $100,000 Total Costs)

5-10

Use of informatics solutions to diagnose cases

1-5

Use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines

1-5

Learn More Contact OSR to Apply

Topics: Clinical Trial, Computational Analysis, Diagnostics, Antibody Detection, Diagnostic Efficacy, Diagnostic Reliability, Diagnostic Scalability, Viral Detection, Epidemiology, Clinical History, Clinical Outcome, Incidence, Risk Factors, Research Methods, Research Model Development, Treatments, Antibody-based Treatment, Convalescent Serum, Drug Development, Drug Repurposing, Drug Targets, Drugs, Immunological Response Targets